Sign in
CompletedPhase 2/3

Effect of Colchicine on the Progression of Aortic Valve Stenosis - A Pilot Study

Key facts

Who runs it
Ottawa Heart Institute Research Corporation
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
24 people enrolled
Started
1 Jul 2022
Ended
20 Jan 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Colchicine 0.6 mg
  • Placebo
Record updated
6 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • mild to moderate aortic stenosis defined by a mean pressure gradient using transthoracic echocardiography (TTE) between 15-25mmHg
  • age greater than18 years
  • given informed consent

Who cannot take part

  • Use of p-glycoprotein inhibitor (e.g. cyclosporine, verapamil, or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, clarithromycin, or ketoconazole)
  • decompensated heart failure
  • active infection (e.g. pneumonia, active skin infections, and on antibiotics)
  • immune compromise (e.g. recurrent infection)
  • history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix)
  • active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate))
  • glomerular filtration rate (GFR) <50 ml/min/1.72m2
  • Hemoglobin < 105(women) <110 (men) g/L; WBC < 3.0x 10(9)/L, platelet count< 110x 10(9)/L
  • Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease or with alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal
  • bicuspid aortic valve
  • associated moderate to severe aortic regurgitation
  • associated other valvular pathology of moderate or greater severity
  • LV dysfunction (EF<50%)
  • chronic diarrhea
  • pregnancy (all women of child bearing potential will have a negative BHCG test
  • breastfeeding
  • Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception
  • unable to give informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

COPAS pilot is a pilot single center double blinded randomized study to determine the effect of targeted anti-inflammation therapy using colchicine, on valvular calcification activity using imaging, i.e. aortic valvular NaF uptake. The current proposal uses a randomized design to evaluate the effect of colchicine vs. placebo on valvular calcification activity over 6 months measured using NaF PET

The 2 groups in the trial

  • ColchicineTreatment being tested

    Colchicine 0.6mg PO daily for 6 months

    Treatment: Colchicine 0.6 mg

  • PlaceboPlacebo, for comparison

    Placebo tablet daily for 6 months

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
6 May 2026